Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is limited by acquired resistance driven b...

Source: Molecular Cancer - May 13, 2020 Category: Cancer & Oncology Authors: Tao Zhang, Rong Qu, Shingpan Chan, Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun & hellip; Tags: Research Source Type: research